Drug intelligence / Profile preview

Naohuan Dan + idebenone

Development stage: Preclinical
Lead developer: Sun Yat-Sen Memorial Hospital
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of Naohuan Dan (a traditional Chinese medicine) and idebenone (a synthetic drug) being investigated for the treatment of mild cognitive impairment (MCI) with kidney deficiency and phlegm stasis syndrome. This combination approach represents an integration of traditional Chinese medicine and Western medicine for cognitive disorders. The treatment aims to improve cognitive function, daily living abilities, depression levels, and Traditional Chinese Medicine clinical symptoms in MCI patients.

Targets

Mitochondrial respiratory complex I – FMN-associated secondary quinone siteNQO1bc1 complex (Cytochrome bc1 complex (plasmodium))NADH:ubiquinone oxidoreductase subunit family

Beyond the preview

Go deeper on Naohuan Dan + idebenone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naohuan Dan + idebenone.

Explore the full profile